MS4A1 and B-cell chronic lymphocytic leukemia: Immunotherapeutic strategies, including bispecific antibodies (such as epcoritamab and glofitamab) and CAR-T cell therapies targeting CD19 and CD20, have shown promise in treating relapsed/refractory CLL.